News: A concensus on the Rx for PCOS infertility

Article

Treatment of infertility in women with polycyctic ovary syndrome (PCOS).

Experts from around the globe met recently in Greece to develop a consensus regarding treatment of infertility in women with polycystic ovary syndrome (PCOS).

They agreed that before considering medical treatment, physicians should counsel patients on the importance of lifestyle changes including weight reduction, exercise, smoking, and alcohol consumption.

They also agreed that treatment should be tailored to each patient's individual circumstances, but that generally first-line treatment should consist of the anti-estrogen clomiphene citrate (CC) for ovulation induction. If this fails to result in pregnancy, second-line treatment should consist of either exogenous gonadotropins with intense monitoring of ovarian response because of the high chance for multiple pregnancy or laparoscopic ovarian surgery. Because the latter as a lone method is effective in fewer than 50% of women, additional ovulation induction medication is usually required. Treatment with CC and gonadotropins is associated with a cumulative singleton live-birth rate of 72%. Third-line treatment should consist of in vitro fertilization.

Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril. 2008;89:505-522.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Neal Barnard, MD, FACC, highlights AMA's new breast cancer prevention guidelines | Image Credit: pcrm.org.
Zachary Wagner, PhD, discusses the harms of bias in reproductive care | Image Credit: ornsife.usc.edu.
Ciera Kirkpatrick, PhD, shows how TikTok is transforming cervical cancer awareness | Image Credit: linkedin.com.
Maria Gallo, PhD, discusses high attendance at crisis pregnancy centers | Image Credit: © x.com.
Related Content
© 2025 MJH Life Sciences

All rights reserved.